<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499614</url>
  </required_header>
  <id_info>
    <org_study_id>FoRT 01/2014</org_study_id>
    <nct_id>NCT02499614</nct_id>
  </id_info>
  <brief_title>Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)</brief_title>
  <acronym>METROS</acronym>
  <official_title>Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or MET Exon 14 Mutation or ROS1 Translocation (METROS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca Traslazionale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Ricerca Traslazionale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, two arms, parallel, non comparative study with crizotinib in patients with ROS 1
      translocation or MET amplification or MET exon 14 mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, prospective, two arms, parallel, non comparative study with crizotinib in
      pretreated NSCLC patients with ROS1 translocation or MET amplification or MET exon 14
      mutation (figure 1). Patients with locally advanced or metastatic NSCLC, pretreated with at
      least one previous chemotherapy line and with at least one measurable tumor lesion will be
      considered eligible for the trial. All potentially eligible patients will be evaluated for
      MET and ROS1 by FISH to detect MET amplification or ROS1 translocation. MET mutation will be
      assessed using direct sequencing or high sensitive methods. After evaluation of inclusion and
      exclusion criteria, and after signature of informed consent form, all MET amplified or MET
      exon 14 mutation or ROS1 translocated eligible patients will receive crizotinib 250 mg BID
      p.o until disease progression, unacceptable toxicity or patient refusal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to crizotinib in patients with ROS1 translocation or MET amplification or MET exon 14 mutation</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity analysis: Incidence of Grade 3-4 Grade Toxicity graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with additional tumor biomarkers in tumor tissue or blood</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response according to different levels of ROS1 translocation or MET amplification (ratio &gt;2.2 and &lt;5 versus ratio ≥ 5) or MET exon 14 mutation</measure>
    <time_frame>From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Patients with MET amplification or MET exon 14 mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ROS1 translocation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered</description>
    <arm_group_label>Patients with MET amplification or MET exon 14 mutation</arm_group_label>
    <arm_group_label>Patients with ROS1 translocation</arm_group_label>
    <other_name>XALKORI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of NSCLC

          -  Availability of tumor tissue for ROS1 and MET analyses

          -  Patient positive for ROS1 translocation or MET amplification

          -  At least one radiological measurable disease according to RECIST criteria (Response
             Evaluation Criteria in Solid Tumors )

          -  At least 1 previous standard chemotherapy regimen

          -  Performance status 0-2 (ECOG)

          -  Patient compliance to trial procedures

          -  age ≥ 18 years

          -  Written informed consent

          -  Adequate BM function (ANC ≥ 1.5x109/L, Platelets ≥ 100x109/L, HgB &gt; 9g/dl)

          -  Adequate liver function (bilirubin &lt;G2, transaminases no more than 3xULN/&lt;5xULN in
             present of liver metastases).

          -  Normal level of alkaline phosphatase and creatinine.

          -  If female: childbearing potential either terminated by surgery, radiation, or
             menopause, or attenuated by use of approved contraceptive method [intrauterine
             contraceptive device (IUD), birth control pills, or barrier device] during and for
             ninety(90) days after end of treatment.

        Exclusion Criteria:

          -  No tumor tissue available or patient negative for ROS1 translocation or MET
             amplification

          -  Absence of any measurable lesion

          -  For ROS1+ patients: Previous therapy with crizotinib or any anti-ALK agent

          -  For MET amplified patients: Evidence of MET amplification in tumor tissue collected in
             EGFR mutant patient at time of EGFR-TKI acquired resistance occurrence. An EGFR mutant
             patient is eligible if MET amplification is detected in a tumor specimen collected
             before starting an EGFR-TKI

          -  No previous chemotherapy

          -  Concomitant radiotherapy or chemotherapy.

          -  Previous radiotherapy on the target lesion(s). If all sites were included in
             radiotherapy fields patient is eligible only if there is evidence of progressive
             disease after completion of radiotherapy.

          -  Symptomatic brain metastases

          -  Diagnosis of any other malignancy during the last 5 years, except for in situ
             carcinoma of cervix uteri and squamous cell carcinoma of the skin

          -  Pregnancy or lactating

          -  Other serious illness or medical condition potentially interfering with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucio Crinò</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Cappuzzo</last_name>
    <phone>+39 010 8398491 / 92</phone>
    <email>f.cappuzzo@fondazionefort.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Forlì- Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Delmonte</last_name>
      <phone>+39 0543739100</phone>
      <email>angelo.delmonte@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Versilia- Oncologia</name>
      <address>
        <city>Camaiore</city>
        <state>Lucca</state>
        <zip>55041</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale per gli Infermi - Presidio Ospedaliero di Faenza- Unità Operativa di Oncologia Medica</name>
      <address>
        <city>Faenza</city>
        <state>Ravenna</state>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Tamberi</last_name>
      <phone>+39 0546601274</phone>
      <email>s.tamberi@ausl.ra.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I°- Unità Operativa di Oncologia</name>
      <address>
        <city>Lugo</city>
        <state>Ravenna</state>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Dazzi</last_name>
      <phone>+39 0545214088</phone>
      <email>c.dazzi@ausl.ra.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A. O. &quot;Ospedale di Circolo&quot; di Busto Arsizio- Struttura Complessa di Oncologia Medica</name>
      <address>
        <city>Saronno</city>
        <state>Varese</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Verusio</last_name>
      <phone>+39 029613576</phone>
      <email>cverusio@aobusto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Gori</last_name>
      <phone>+39 0456013472</phone>
      <email>stefania.gori@sacrocuore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Bracarda</last_name>
      <phone>+39 0575255438</phone>
      <email>sergio.bracarda@usl8.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;S.G. Moscati&quot;- U.O. di Oncologia Medica</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Gridelli</last_name>
      <phone>0825203945</phone>
      <email>cgridelli@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;- U.O. Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Galetta</last_name>
      <phone>+39 0805555418</phone>
      <email>galetta@teseo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi- S.C. Oncologia Medica 1</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Di Costanzo</last_name>
      <phone>+39 0557947298</phone>
      <email>adicostanzo.oncmed@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Grossi</last_name>
      <phone>+39 0105600385</phone>
      <email>fg1965@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Livorno- U.O. Dipartimento di Oncologia Medica</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Cappuzzo</last_name>
      <phone>+39 0586223189</phone>
      <email>f.cappuzzo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Campo di Marte- U.O.C. di Oncologia Medica</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia - Divisione di Oncologia Toracica</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo De Marinis, MD</last_name>
      <phone>+39 0257489482</phone>
      <email>Filippo.DeMarinis@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Barbieri</last_name>
      <phone>+39 0594224385</phone>
      <email>barbieri.fausto@policlinico.mo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Giovanni Pascale&quot;- Oncologia Medica Dipartimento Toraco-Polmonare</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Morabito</last_name>
      <phone>+39 0815903631</phone>
      <email>alessandro.morabito@usc-intnapoli.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. &quot;Maggiore della Carità&quot;- Dipartimento Oncologico</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Borra</last_name>
      <phone>+39 03213733989</phone>
      <email>gloria.borra@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS- UOS Oncologia Toracica UOC. Oncologia Medica 2</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Favaretto</last_name>
      <phone>+39 0498215620</phone>
      <email>agfavaretto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena- U.O. Oncologia medica</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Gebbia</last_name>
      <phone>+39 0916806111</phone>
      <email>vittorio.gebbia@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma- Struttura Complessa di Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Tiseo</last_name>
      <phone>+39 0521702316</phone>
      <email>mtiseo@ao.pr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucio Crinò, MD</last_name>
      <phone>0755784099</phone>
      <email>lucio.crino@ospedale.perugia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana (AOUP)- Pneumo-Oncologia - Dipartimento Cardio-Toracico</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Chella</last_name>
      <phone>+39 050995340</phone>
      <email>anto.kell@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Ravenna- Oncologia Medica</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Cappuzzo</last_name>
      <phone>+39 0544285247</phone>
      <email>f.cappuzzo@googlemail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot; Rimini- UU.OO. Oncologia ed Ematologia</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximilian Papi</last_name>
      <phone>+39 0541705413</phone>
      <email>mpapi@auslrn.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osp. Civile SS. Annunziata- U.O.C di Oncologia Medica</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Bria</last_name>
      <phone>+39 0458128124</phone>
      <email>emiliobria@yahoo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fondazionefort.org/</url>
    <description>Fondazione FoRT</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MET amplification</keyword>
  <keyword>ROS1 translocation</keyword>
  <keyword>Crizotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

